相关实验视频
Updated: Jul 14, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
托法西提尼布用于抗TNF耐药性性直肠炎患者:来自GETAID的多中心队列研究
Mathieu Uzzan1, Maria Nachury1, Alexandre Nuzzo2
1University of Lille, CHU Lille, Institute for Translational Research in Inflammation, Lille, France.
托法西提尼布显示出治疗性直肠炎 (UP) 的潜力,在一项对耐药患者的研究中观察到显著的无类固醇缓解和临床反应率. 需要进一步的研究来证实这些发现对UP治疗.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性直肠炎 (UP) 显著影响生活质量.
- 由于历史的试验排除,UP的治疗疗效一直没有得到充分研究.
- 评估托法西提尼布在UP中的有效性和安全性至关重要.
研究的目的:
- 评估托法西提尼布在治疗性直肠炎中的有效性.
- 评估托法西提尼布在UP患者中的安全性.
- 为了确定耐火UP的缓解和响应率.
主要方法:
- 在17个GETAID中心进行了回顾性多中心研究.
- 包括连续接受托法西提尼布治疗的UP患者.
- 主要终点:无类固醇缓解 (8至14周);次要:临床反应和1年缓解.
主要成果:
- 42.9%的患者获得了无类固醇缓解,60.0%的患者在诱导后获得了临床反应.
- 一年后,39.4%的患者有无类固醇缓解,45.5%的患者有临床反应.
- 较低的基线部分梅奥得分预测缓解;报告了一次严重的不良事件 (败血性休克).
结论:
- 托法西提尼布在耐火性性前列炎中显示出治疗潜力.
- 该药物为那些治疗选择有限的患者提供了可行的选择.
- 需要对托法西提尼布在UP的长期疗效和安全性进行进一步的研究.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...